AEON
Aeon Biopharma Inc
$
0.657
- Overview
- Forecast
- Valuation
- Earnings
Line
|
Candle
1D
5D
1M
3M
6M
YTD
1Y
5Y
High
0.730
Open
0.7281
VWAP
0.67
Vol
134.18K
Mkt Cap
7.42M
Low
0.630
Amount
89.26K
EV/EBITDA(TTM)
--
Total Shares
39.12M
EV
10.82M
EV/OCF(TTM)
--
P/S(TTM)
--
AEON Biopharma, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing its botulinum toxin complex, ABP-450 (prabotulinumtoxinA) injection or ABP-450, for debilitating medical conditions, with an initial focus on the neuroscience market. ABP-450 is a 2-chain polypeptide, a heavy chain joined by a bond to a light chain. ABP-450 interferes with nerve impulses by inhibiting the release of acetylcholine into the neuromuscular junction, causing a flaccid paralysis of muscles. The active biologic ingredient in ABP-450 is Clostridium botulinum toxin, type A with a complete molecular complex weight of 900 kDa. Its initial development programs for ABP-450 are directed at migraine, cervical dystonia, gastroparesis and post-traumatic stress disorder (PTSD). The Company has completed enrollment and dosing of patients for a Phase II double blind study of ABP-450 for the treatment of both chronic and episodic migraine.
Show More
Market Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q2
FY2025Q1
FY2024Q4
--
--
-0.350
-106.56%
--
--
-13.680
-86.95%
--
--
-12.960
-74.65%
Estimates Revision
Stock Price
Go Up
+33.46%
In Past 3 Month
Valuation Metrics
The current forward P/E ratio for Aeon Biopharma Inc (AEON.A) is 0.00, compared to its 5-year average forward P/E of -0.89. For a more detailed relative valuation and DCF analysis to assess Aeon Biopharma Inc 's fair value, click here.
Forward PE
The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
N/A
5Y Average PE
-0.89
Current PE
0.00
Overvalued PE
4.00
Undervalued PE
-5.79
Forward EV/EBITDA
The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
N/A
5Y Average EV/EBITDA
0.00
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
0.00
Undervalued EV/EBITDA
0.00
Forward PS
The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
N/A
5Y Average PS
0.00
Current PS
0.00
Overvalued PS
0.00
Undervalued PS
0.00
Financials
Annual
Quarterly
FY2025Q1
YoY :
-61.95%
-3.95M
Operating Profit
FY2025Q1
YoY :
-107.71%
9.10M
Net Income after Tax
FY2025Q1
YoY :
-101.00%
2.28
EPS - Diluted
FY2025Q1
YoY :
-7.99%
-7.91M
Free Cash Flow
Trading Trends
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
3
84.5K
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
0-3
Months
0.0
Volume
0
3-6
Months
0.0
Volume
0
6-9
Months
0.0
Volume
0
0-12
Months
0.0
Volume
0
Bought
0-3
0
0.0
Volume
Months
3-6
0
0.0
Volume
Months
6-9
0
0.0
Volume
Months
0-12
0
0.0
Volume
Months
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
3
84.5K
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
AEON News & Events
Events Timeline
2025-04-21 (ET)
2025-04-21
16:11:54
Aeon Biopharma appoints Rob Bancroft as CEO
2025-01-06 (ET)
2025-01-06
08:13:48
Aeon Biopharma prices 40M units at 50c in underwritten public offering
2024-09-30 (ET)
2024-09-30
08:05:59
Aeon Biopharma announces outcome from FDA biosimilar advisory meeting
Sign Up For More Events
Sign Up For More Events
News
5.0
05-23NewsfilterAEON Biopharma Reports Inducement Grants Under NYSE American LLC Company Guide Section 711
1.0
05-19NewsfilterAEON Biopharma to Present at the Aegis Capital Corp. Virtual Conference 2025
7.0
04-25NewsfilterAEON Biopharma Announces NYSE American Acceptance of Plan to Regain Listing Compliance
Sign Up For More News
People Also Watch
HWH
HWH International Inc
1.530
USD
+3.38%
TXMD
TherapeuticsMD Inc
1.080
USD
+1.79%
LEDS
SemiLEDs Corp
1.806
USD
+11.48%
HTOO
Fusion Fuel Green PLC
4.380
USD
+3.06%
SSKN
Strata Skin Sciences Inc
1.899
USD
+6.69%
JBDI
JBDI Holdings Ltd
0.980
USD
-2.00%
WBUY
Webuy Global Ltd
2.990
USD
-5.08%
HCWC
Healthy Choice Wellness Corp
0.400
USD
-2.44%
YYAI
Connexa Sports Technologies Inc
4.110
USD
-13.47%
CISO
CISO Global Inc
0.930
USD
-1.27%
FAQ
What is Aeon Biopharma Inc (AEON) stock price today?
The current price of AEON is 0.6566 USD — it has decreased -6.54 % in the last trading day.
What is Aeon Biopharma Inc (AEON)'s business?
What is the price predicton of AEON Stock?
What is Aeon Biopharma Inc (AEON)'s revenue for the last quarter?
What is Aeon Biopharma Inc (AEON)'s earnings per share (EPS) for the last quarter?
What changes have occurred in the market's expectations for Aeon Biopharma Inc (AEON)'s fundamentals?
How many employees does Aeon Biopharma Inc (AEON). have?